Visby Medical announced two new relationships that will expand national access to the Visby Women’s Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexually transmitted infections (STIs) available to consumers, enabling immediate access to Visby’s integrated "Test-to-Treat" ecosystem. The palm-sized device delivers confidential results in just 30 minutes, providing women with a rapid response for chlamydia, gonorrhea, and trichomoniasis from the comfort and privacy of the home.
In a separate agreement, Labcorp OnDemand, Labcorp’s digital platform for convenient at-home and in-person testing, and Ovia Health, a leading women’s health app that supports the full spectrum of women’s and family health, announced it will now offer the Visby Rapid PCR At-Home Female STI Test to consumers.
The Visby Women’s Sexual Health Test was designed to close gaps in STI testing. Unlike most at-home STI kits, which require mailing samples to a lab or retesting to confirm results, Visby’s test uses PCR technology to deliver lab-accurate results in just 30 minutes. Users collect a simple vaginal swab, insert it into the device, and get results through Visby’s secure app.
Since November 2025, the Visby Women’s Sexual Health Test has been available for purchase on questhealth.com. The test is also now available via Labcorp OnDemand. In early 2026, Ovia Health by Labcorp will also work to offer the Visby solution to its employer and health plan partners. The expansion of availability of Visby’s Women Sexual Health Test comes on the heels of Visby Medical’s nationwide launch of its STI test in November, removing long-standing gaps in care.
